NCT03175172 - Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

January 9, 2018

Study Completion Date

January 31, 2018

Conditions

Malignant Pleural Mesothelioma

Interventions

BIOLOGICAL

CRS-207

Administered by IV infusion over approximately 1 hour.

BIOLOGICAL

Pembrolizumab

Administered by IV infusion over approximately 30 minutes.

Trial Locations (8)

Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

NIH National Cancer Institute, Bethesda

H. Lee Moffitt Cancer Center, Tampa

Cleveland Clinic Foundation, Cleveland

Mayo Clinic, Rochester

University of Chicago Medical Center, Chicago

UCSF Comprehensive Cancer Center, San Francisco